<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02769351</url>
  </required_header>
  <id_info>
    <org_study_id>UF-HF-01-INT</org_study_id>
    <secondary_id>DRKS00009836</secondary_id>
    <nct_id>NCT02769351</nct_id>
  </id_info>
  <brief_title>Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration</brief_title>
  <acronym>GENTLE-UF</acronym>
  <official_title>A Multicentre, Prospective Registry to Evaluate the Safety and Efficacy of Minimally Invasive Ultrafiltration Treatment and Its Effect on Symptoms and Rehospitalisation in Patients With Advanced Volume Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with advanced volume overload, minimally invasive ultrafiltration treatment in
      the acute phase can have a positive effect on clinical outcome. The aim is to collect
      treatment data in the context of a prospective registry of the safety and performance of
      minimally invasive ultrafiltration. The data will be recorded via an electronic case report
      form (eCRF); the eCRF runs on a server located in Germany and complies with current data
      protection regulations. It is intended to include about 300-500 patients with advanced volume
      overload at a minimum of 10 sites. In addition, data on a disease management programme
      (in-body measurement and home monitoring) will be recorded in up to 40 of these patients. The
      treatment data from each patient will be recorded over 12 months. An interim analysis will be
      performed after 150 patients have been observed for 6 months. The knowledge about
      ultrafiltration in volume overload obtained from the registry, in some cases in combination
      with a disease management programme, is intended to improve the body of evidence. In
      addition, the data will be used for hypothesis generation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There may be various reasons why an increased accumulation of fluid occurs in tissue. The
      most common causes include heart failure, kidney failure or cirrhosis of the liver. In rare
      cases, oedema can develop following septicaemia. The usual treatment of oedema involves
      diuretics, i.e. water tablets, which remove excess fluid from the body and which can be
      administered either orally or intravenously. For some years now, it has also been possible to
      use ultrafiltration to treat oedema. This involves filtering and removing excess fluid from
      the blood. This individual method enables a precisely defined amount of fluid to be
      withdrawn. Access to the blood circulation is usually via a central venous catheter, as in
      acute dialysis. Current international treatment guidelines recommend that consideration
      should be given to ultrafiltration therapy in the context of treatment of diuretic-resistant
      volume overload (e.g. second- or third-line therapy for acute decompensated heart failure).
      There are, however, to date no clinical data on a combined treatment regimen of diuretics and
      supportive ultrafiltration. Accordingly, ultrafiltration may be included in clinical
      guidelines either only with a low level of evidence (e.g. IIb in the ACCF/AHA guidelines) or
      not at all (ESC guidelines). The main reasons for the limited body of evidence for
      ultrafiltration are, on the one hand, the invasive nature of the usual procedures (these
      usually require the insertion of a central venous catheter) and structural barriers in the
      health system (ultrafiltration is normally offered by nephrologists and not by
      cardiologists). With an increasing clinical need and limited medical alternatives,
      particularly in view of the frequently occurring diuretic resistance in heart failure, there
      is an urgent medical need to fill this gap in evaluation evidence. In the context of the
      registry, the CHIARA system, a minimally invasive (i.e. via a peripheral venous access)
      extracorporeal ultrafiltration system, is used for the treatment of decompensated volume
      overload. The CHIARA system has a CE mark for the intended purpose of ultrafiltration of the
      blood of patients suffering from heart failure, acute or chronic renal failure or excess body
      fluid. It is planned to use the medical device in connection with this intended purpose only.
      In participating hospitals, patients will be treated with this new treatment strategy of
      minimally invasive ultrafiltration treatment in support of diuretic drug therapy in the acute
      phase of volume overload. It is possible with the use of ultrafiltration therapy to control
      volume overload and reduce it on an individual basis, so that diuretics can be given
      sparingly and, as a consequence, diuretic resistance and a deterioration of renal function
      due to diuretic uptitration can be avoided.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Rehospitalisation (yes/no) due to exacerbation of heart failure/volume overload of other origin</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Significant deterioration of kidney function</measure>
    <time_frame>up to 96h after end of ultrafiltration treatment</time_frame>
    <description>Significant deterioration of kidney function (on the basis of kidney retention parameters and eGFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant electrolyte shift</measure>
    <time_frame>up to 96h after end of ultrafiltration treatment</time_frame>
    <description>(serial measurement of electrolytes according to clinical requirements: sodium, potassium)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural symptomatic hypotension</measure>
    <time_frame>periprocedural</time_frame>
    <description>Periprocedural (= emerging during the ultrafiltration treatment) symptomatic hypotension (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural-, device-, venous access related events</measure>
    <time_frame>up to 96h after end of ultrafiltration treatment</time_frame>
    <description>Events: related to venous access, apparatus-related, anticoagulation-related, UF procedure-related, unrelated</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Acute Heart Failure</condition>
  <condition>Cardiac Decompensation</condition>
  <condition>Volume Overload</condition>
  <arm_group>
    <arm_group_label>periph. minimal invasive ultrafiltration</arm_group_label>
    <description>Patients with volume overload receiving ultrafiltration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>periph. minimal invasive ultrafiltration</intervention_name>
    <description>ultrafiltration via a peripheral single-needle</description>
    <arm_group_label>periph. minimal invasive ultrafiltration</arm_group_label>
    <other_name>ultrafiltration</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with minimally invasive ultrafiltration in support of diuretic drug
        therapy in the acute phase of volume overload.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥18 years

          -  Inpatient-treated patients with acute volume overload, preferably in association with
             cardiac decompensation with signs of incipient diuretic resistance (lack of increase
             in urine output despite significant escalation of diuretic therapy; e.g. ≥80 mg
             furosemide / 24 h or less than 1375 mL urine output/40 mg furosemide per 24 h or
             equivalent dose of other loop diuretics [established clinically or from the medical
             history])

          -  New York Association Functional Class (NYHA) III-IV at inclusion

          -  Systolic or diastolic cardiac dysfunction (HF-REF or HF-PEF)

          -  Adequate venous access (preferably peripheral arm vein) allowing a flow rate ≥ 60 mL /
             min

          -  Written consent to the use of data in the registry (where necessary, by a legal
             guardian).

        Exclusion Criteria:

          -  Contraindication to anticoagulation (e.g. known heparin-induced thrombocytopenia,
             severe bleeding)

          -  Terminal renal failure (stage V, GFR &lt;15 mL)

          -  Cardiogenic shock, e.g. in association with acute coronary syndrome (ACS)

          -  Other diseases or factors that, in the study doctor's opinion, constitute a potential
             contraindication to ultrafiltration

          -  Pregnant women, women in labour, breast-feeding women or women of childbearing
             potential, who are without adequate contraception or are planning a family. NB: a
             pregnancy test is performed systematically in women of childbearing age and the
             patient is not included in the event of pregnancy (positive test). It is absolutely
             essential that women, who have a negative test and who are included in the study, have
             an effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning T Baberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinikum Berlin Buch, Berlin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer C Franke, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fresenius Medical Care Deutschland GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer C Franke, MD</last_name>
    <phone>+49 (0)6172 609</phone>
    <phone_ext>7786</phone_ext>
    <email>Jennifer.Franke@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eva Bruder</last_name>
    <phone>+49 (0)6172 609</phone>
    <phone_ext>2370</phone_ext>
    <email>Eva.Bruder@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lutz Frankenstein, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hugo A Katus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lutz Frankenstein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Zeier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Morath, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden Württemberg</state>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vedat Schwenger, MD</last_name>
      <phone>+49 (0)711 278</phone>
      <phone_ext>35301</phone_ext>
    </contact>
    <investigator>
      <last_name>Vedat Schwenger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Schwerin</name>
      <address>
        <city>Schwerin</city>
        <state>Mecklemburg Pomerania</state>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Rhein</last_name>
      <email>gabriele.rhein@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Jens Nürnberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander Staudt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <state>Niedersachsen</state>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan T Kielstein, MD</last_name>
      <phone>+49 (0)531-595</phone>
      <phone_ext>2220</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Reinhard Wanninger, MD</last_name>
      <phone>+49 (0)531-595</phone>
      <phone_ext>2220</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Jan T Kielstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reinhard Wanninger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Hildesheim</name>
      <address>
        <city>Hildesheim</city>
        <state>Niedersachsen</state>
        <zip>31135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Burkhard Kreft, MD</last_name>
      <phone>+49 (0)5121-894</phone>
      <phone_ext>3002</phone_ext>
    </contact>
    <investigator>
      <last_name>Burkhard Kreft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jürgen Tebbenjohanns, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinik Attendorn</name>
      <address>
        <city>Attendorn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>57439</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan A Doldi, MD</last_name>
      <phone>+49 (0)2722 60</phone>
      <phone_ext>2311</phone_ext>
    </contact>
    <investigator>
      <last_name>Stephan A Doldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrzej Wierucki, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <state>North Rhine-Westphalia</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jürgen Floege, MD</last_name>
      <email>imundt@ukaachen.de</email>
    </contact>
    <investigator>
      <last_name>Jürgen Floege, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolaus Marx, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <state>North Rhine-Westphalia</state>
        <zip>47053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriele Schott, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gabriele Schott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolfgang Lepper, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudia Panz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt</name>
      <address>
        <city>Erfurt</city>
        <state>Thueringen</state>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Grützfeld</last_name>
      <email>natalia.gruetzfeld@helios-kliniken.de</email>
    </contact>
    <investigator>
      <last_name>Harald Lapp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christoph C Haufe, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ulrich P Hinkel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Berlin Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saban Elitok, MD</last_name>
      <phone>+49 (0)30 94 01</phone>
      <phone_ext>12900</phone_ext>
    </contact>
    <investigator>
      <last_name>Henning T Baberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Saban Elitok, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital Gothenburg</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clara Hjalmarsson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Clara Hjalmarsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Entela Bollano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christian Templin, MD</last_name>
      <phone>+41 44 255 39 18</phone>
    </contact>
    <investigator>
      <last_name>Frank Ruschitzka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Templin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://drks-neu.uniklinik-freiburg.de/drks_web/setLocale_DE.do</url>
    <description>German Clinical Trials Register (DRKS)</description>
  </link>
  <reference>
    <citation>Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 Oct 15;62(16):e147-239. doi: 10.1016/j.jacc.2013.05.019. Epub 2013 Jun 5.</citation>
    <PMID>23747642</PMID>
  </reference>
  <reference>
    <citation>McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69. doi: 10.1093/eurjhf/hfs105. Erratum in: Eur J Heart Fail. 2013 Mar;15(3):361-2.</citation>
    <PMID>22828712</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>August 15, 2016</last_update_submitted>
  <last_update_submitted_qc>August 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volume overload</keyword>
  <keyword>heart failure</keyword>
  <keyword>cardiac decompensation</keyword>
  <keyword>ultrafiltration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Overall results will be published. Individual participant data will not be made available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

